Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THPP-6
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
THPP-6 is a small-molecule, selective phosphodiesterase 10A (PDE10A) inhibitor developed by Merck. It has been investigated in preclinical models for its potential antipsychotic efficacy and its role in regulating energy homeostasis, caloric intake, and body weight. In diet-induced obesity (DIO) mouse models, THPP-6 treatment has been shown to suppress food intake, increase energy expenditure, promote white adipose tissue (WAT) browning (beiging), and improve insulin sensitivity, suggesting potential metabolic benefits over standard atypical antipsychotics.
- Other names
- 2-(6-chloropyridin-3-yl)-4-[(2S)-1-methoxypropan-2-yl]oxy-N-(6-methylpyridin-3-yl)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxamide
02
Targets
PDE10A (Phosphodiesterase 10A)
Beyond the preview
Go deeper on THPP-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THPP-6.